SeptiCyte® technology can assess a patient’s dysregulated immune response by quantifying and analyzing gene expression signatures from whole blood, providing an accurate sepsis diagnosis and actionable results in about an hour, to guide the physician in optimizing patient management decisions.
The dysregulated immune response is a sepsis indicator, the key to unlocking a sepsis diagnosis, and initiating sepsis treatment of patients suspected of sepsis. The human immune system responds specifically to an invading pathogen and produces an abundant genetic signal of blood biomarkers that is reliably detected by SeptiCyte® technology. Using mathematical algorithms, a patient’s genetic material from the septic dysregulated immune response is rapidly analyzed, providing an actionable sepsis diagnosis in suspected sepsis cases.
Determining infection status in suspected sepsis patients has traditionally focused on characterization and identification of pathogens, for example by microbiological culture.
Detection of an invading pathogen by blood culture is often slow with no identification in the majority of suspected sepsis cases. However, the immune system responds specifically to an invading pathogen and, in the case of sepsis, produces an intense dysregulated immune response that is reliably detected by SeptiCyte® technology.
How to improve accuracy and accessibility to a fast sepsis test?
SeptiCyte® technology does not focus on the identification of pathogens, but rather on the detection of the dysregulated host immune response that is a hallmark of sepsis. SeptiCyte® technology utilizes this as the key to unlocking a sepsis diagnosis, which in turn can lead to the appropriate initiation of therapeutic treatment of patients suspected of sepsis.
Immune cells contain variable amounts of many specific messenger RNAs which together provide a ‘snapshot’ or profile of the host response to the invading pathogen. Our algorithmic approach quantifies specific mRNAs within the patient’s immune response, and rapidly reports an actionable sepsis diagnosis in 100% of suspected sepsis cases.
Immunexpress’ SeptiCyte® RAPID test is the only on-market FDA-cleared molecular lab sepsis test for the management of sepsis using the patient’s immune response to infection. Multi-national clinical trials have shown SeptiCyte® technology to be the single most accurate sepsis test for the diagnosis of sepsis.
Minimize the chance of false negative and false positive results by combining data from a dysregulated immune response assay with pathogen information.
SeptiCyte® host response results allow clinicians to better interpret positive and negative pathogen results.